Dr. Thomas Hendrix Beckham, MD, PhD

Dr. Beckham practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Beckham's NPI, 1043604457, was assigned on March 24, 2015. Dr. Beckham graduated from Medical University of South Carolina (MUSC) in 2015. Dr. Beckham holds Texas license S5120.

Dr. Beckham's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Beckham's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Beckham practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Beckham's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Beckham is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Beckham's licenses on file in 10 states: Texas, Florida, Arizona, Georgia, Alabama, Louisiana, Mississippi, Oklahoma, Tennessee and Washington.

Dmand AI lists bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Beckham treats.

CMS data shows 1,075 Medicare services from Dr. Beckham across 16 procedure codes in 2024, for 148 Medicare patients. Medicare paid $91,113 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 148 Medicare patients who saw Dr. Beckham in 2024. The largest group is 65 to 74, with 90 patients. 75% of them have high blood pressure, and 74% have cancer. 8% are also on Medicaid. Their average risk score is 2.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Beckham's median patient age at 70, with 48% women.

In 2024, Dr. Beckham wrote 32 Medicare Part D claims for 22 patients. 97% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $233 in total drug cost. In 2023, CMS named 52 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Beckham for performance year 2024, reported as part of a group. Dr. Beckham accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Beckham as offering telehealth.

Dmand AI links 46 papers to Dr. Beckham, published from 2008 to 2025. 2019 was the busiest year, with 8. The most frequent topics are Antineoplastic Agents, Cell Line, Tumor and Prostatic Neoplasms. Dr. Beckham has published most often in Adv Radiat Oncol. Dr. Beckham's most frequent co-authors are Amol J. Ghia, MD, Chenyang Wang, MD and Debra N. Yeboa, MD.

CMS Open Payments shows 18 general payments to Dr. Beckham from 3 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 40% of the total. GT Medical Technologies, Inc paid the most, $8,652.

Dr. Beckham graduated from Medical University of South Carolina (MUSC) in 2015.

Dr. Beckham is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.